Skip to main content

Table 6 Distribution of patients with SLE flare

From: Risk factors for the flare of systemic lupus erythematosus and its influence on prognosis: a single-center retrospective analysis

  Pulmonary hypertension Serositis Anemia associated with SLE
Yes
(N = 20)
No
(N = 101)
Yes
(N = 35)
No
(N = 86)
Yes
(N = 50)
No
(N = 71)
Age (Year), mean (SD) 41.3(11.8) 39.7(13.4) 37.7(12.7) 40.9(12.3) 37.6(13.8) 41.6(12.5)
Gender (female/male) 20/0 93/8 34/1 79/7 47/3 66/5
Disease duration (Month), mean (SD) 109.6(79.5) 89.9(80.2) 93.1(85.3) 93.2(78.4) 86.3(71.1) 98.0(86.0)
SLEDAI-2 K,mean (SD) 12.1(8.0) 11.8(5.9) 15.2(5.5) 10.5(6.1) 14.4(5.8) 10.1(5.9)
Initial treatment
 Glucocorticoid amount (mg/kg/d), mean (SD) 0.80(0.22) 0.95(0.97) 0.89(0.34) 0.94(1.04) 0.88(0.37) 0.96(1.13)
 Hydroxychloroquine, n (%) 18(90.0) 80(79.2) 30(85.7) 68(79.1) 43(86.0) 55(77.5)
Immunosuppressive therapy, n (%) 7(35.0) 42(41.6) 12(34.3) 37(43.0) 19(38.0) 30(42.3)
 Regular maintenance treatment, n (%) 3(15.0) 53(52.5) 9(25.7) 47(54.7) 14(28.0) 42(59.2)
 maintenance therapy < 1 year, n (%) 6(30.0) 14(13.9) 9(25.7) 11(12.8) 7(14.0) 13(18.3)
 maintenance therapy < 2 years, n (%) 8(40.0) 20(19.8) 11(31.4) 17(19.8) 11(22.0) 17(23.9)
 maintenance therapy < 3 years, n (%) 9(45.0) 25(24.8) 12(34.3) 22(25.6) 13(26) 21(29.6)
 maintenance therapy < 4 years, n (%) 14(70.0) 84(83.2) 27(77.1) 71(82.6) 41(82.0) 57(80.3)
 maintenance therapy < 5 years, n (%) 15(75.0) 86(85.1) 29(82.9) 72(83.7) 43(86.0) 58(81.7)
  1. N Number of cases; SLEDAI-2 K Systemic lupus erythematosus disease activity index-2000